The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).
 
Giuseppe Curigliano
Leadership - ESMO; ESMO Open; European Society of Breast Cancer Specialists (EUSOMA=
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celcuity; Daichi-Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; GlaxoSmithKline; Guardant Health; Hengrui Therapeutics; Lilly; Menarini; Merck; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen; Veracyte
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichii Sankyo; Pfizer; Roche/Genentech
 
Xichun Hu
No Relationships to Disclose
 
Rebecca Alexandra Dent
Honoraria - AstraZeneca; Eisai Europe; Lilly; MSD; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Eisai; Merck; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Roche
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Merck; Pfizer; Roche
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Henlius; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Carlos H. Barrios
Stock and Other Ownership Interests - MedSIR; Tummi
Honoraria - Adium Pharma; AstraZeneca; Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi; Zodiac Pharma
Consulting or Advisory Role - AstraZeneca; Libbs; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech; United Medical
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Aveo (Inst); Bayer (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Covance (Inst); Daiichi Sankyo (Inst); Exelixis (Inst); Exelixis (Inst); Gilead Sciences (Inst); ICON Clinical Research (Inst); INC Research (Inst); IQvia (Inst); Janssen (Inst); LabCorp (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Nuvisan (Inst); OBI Pharma (Inst); Parexel (Inst); Parexel (Inst); Pfizer (Inst); PharmaMar (Inst); PPD Global (Inst); PSI (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Servier (Inst); Syneos Health (Inst); Takeda (Inst); TRIO US (Inst); Worldwide Clinical Trials (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS Brazil; Lilly; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Joyce O'Shaughnessy
Honoraria - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Byondis; Carrick Therapeutics; Daiichi Sankyo; DAVA Oncology; Eisai; Fishawack Health; G1 Therapeutics; Genentech; Genzyme; Gilead Sciences; GlaxoSmithKline; Lilly; Loxo/Lilly; Merck; Novartis; Ontada/McKesson; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Stemline Therapeutics; Taiho Oncology; Veru
Consulting or Advisory Role - Abbvie; Agendia; Amgen; Aptitude Health; AstraZeneca; BioNTech; Byondis; Carrick Therapeutics; Daiichi Sankyo; DAVA Oncology; Eisai; Fishawack Health; G1 Therapeutics; Genentech; Genzyme; Gilead Sciences; GlaxoSmithKline; Lilly; Loxo/Lilly; Merck; Novartis; Ontada/McKesson; Pfizer; Pierre Fabre; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Stemline Therapeutics; Taiho Oncology; Veru
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Seagen
Travel, Accommodations, Expenses - Agendia; Aptitude Health; AstraZeneca; Daiichi Sankyo; DAVA Oncology; Eisai; Lilly; Loxo/Lilly; Merck; Novartis; Pfizer; Roche; Seagen
 
Hans Wildiers
Honoraria - MSD (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Astrazeneca (Inst); Augustine Therapeutics (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo Europe GmbH (Inst); Daiichi Sankyo Europe GmbH (Inst); Gilead Sciences (Inst); Immutep (Inst); Lilly (Inst); Lilly (Inst); MSD (Inst); Parexel (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo/Lilly (Inst); Gilead Sciences (Inst); Roche (Inst)
 
Qingyuan Zhang
No Relationships to Disclose
 
Seock-Ah Im
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Hanmi; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Boryung Pharmaceuticals (Inst); Daewoong Pharmaceutical (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Other Relationship - Roche
 
Cristina Saura
Honoraria - AstraZéneca; Daiichi Sankyo/Astra Zeneca; Eisai Europe,Ltd; Phillips Health Works; Puma Biotechnology; Roche Pharma AG; Seagen; Solti; Zymeworks
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; MediTech; Novartis; Pfizer; Pharmalex; Philips Healthcare; Pierre Fabre; Pint Pharma; Puma Biotechnology; Roche; SeaGen; Synthon; Zymeworks
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exeter Pharmaceuticals; Lilly; Pfizer; Pierre Fabre; Puma Biotechnology; Seagen
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (BMS) (Inst); CytomX Therapeutics (Inst); Daiichi Sakyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); InnoUp (Inst); Lilly (Inst); Macrogenics (Inst); Menarini (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai Europe; Novartis; Pfizer; Puma Biotechnology; Roche
Other Relationship - Research funding in the form of third-party medical writing support, furnished by Eleanor Porteous, MSc, of Nucleus Global, an Inizio Company, was provided by F. Hoffmann-La Roche Ltd'
 
Laura Biganzoli
Honoraria - Boehringer Ingelheim; Exact Sciences; Lilly; Novartis; Pfizer
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Exact Sciences; Genomic Health; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Seagen
Research Funding - Celgene (Inst); Genomic Health (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo
 
Joohyuk Sohn
Stock and Other Ownership Interests - Daiichi Sankyo (I)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myerss guibb (Inst); Celcuity (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); Eikon (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hanmi Pharm (Inst); HLB Life Science (Inst); ILDONG PHARMACEUTICAL (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Olema Oncology (Inst); Pfizer (Inst); Qurient (Inst); Roche (Inst); Samyang Holdings (Inst); Sanofi (Inst); Seagan (Inst); Sermonix Pharmaceuticals (Inst)
 
Christelle Levy
Consulting or Advisory Role - Gilead Sciences; Lilly; Seagen
Travel, Accommodations, Expenses - Gilead Sciences; Pfizer
 
Natasha Begbie
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; AstraZeneca (I)
Travel, Accommodations, Expenses - GORE
 
Jun Ke
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Gargi Surendra Patel
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
 
Aditya Bardia
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Genentech; Genentech/Roche (Inst); Gilead Sciences; Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly; Lilly (Inst); Menarini; Menarini (Inst); Merck; Mersana; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Radius Health (Inst); Sanofi
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)